Sankarapillai Jayasankar, Ramamoorthy Thilagavathi, Sarveswaran Gokul, Venugopal Gopika, Mathur Prashant
Indian Council of Medical Research - National Centre for Disease Informatics and Research, Nirmal Bhawan-ICMR Complex (II Floor), Adjacent to Trumpet Flyover of BIAL, Poojanahalli Road, Off NH-7,Kannamangala Post, Karnataka, Bengaluru, 562 110, India.
BMC Cancer. 2025 Jul 1;25(1):1062. doi: 10.1186/s12885-025-14440-1.
AIM: Radiotherapy is a cornerstone of cancer treatment in India, yet its expansion is hindered by high investment costs. Effective planning and target estimation based on cancer burden are crucial to meet the radiotherapy demands of patients with cancer. METHODS: Data from Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used. Epidemiological data on stage, subsite and histology from National cancer registry programme were used to assess the optimal utilization proportion for India. A sensitivity analysis was carried out. Similarly optimal radiotherapy fraction has also being calculated. These measures have been used to estimate the existing radiotherapy utilization gap by comparing with the current radiotherapy utilization from cancer registry as well as estimate the optimal radiotherapy machines required for the country. RESULTS: Optimal radiotherapy utilization rate in India is 58.4% (95% CI: 57.6-58.9), whereas the actual utilization rate is 28.5% (95% CI: 28.0-31.5). The estimated number of radiotherapy machines required to meet demand ranges from 1,585 to 2,545. CONCLUSION: The study highlights a substantial shortfall in radiotherapy utilisation across all cancer types and underscores the need for interventions to meet the gap in machines required for an equitable cancer care. Efforts to reduce the cancer burden in the country shall influence the radiotherapy requirement through early stage diagnosis and treatment. Advancement in other modalities of treatment shall need to watch closely.
目的:放射治疗是印度癌症治疗的基石,但其扩展受到高昂投资成本的阻碍。基于癌症负担进行有效的规划和目标估计对于满足癌症患者的放射治疗需求至关重要。 方法:使用了来自澳大利亚癌症结局研究与评估合作组织(CCORE)的数据。利用国家癌症登记计划中关于分期、亚部位和组织学的流行病学数据来评估印度的最佳利用比例。进行了敏感性分析。同样也计算了最佳放疗分割次数。通过与癌症登记处当前的放疗利用率进行比较,这些措施被用于估计现有的放疗利用差距,以及估计该国所需的最佳放疗设备数量。 结果:印度的最佳放疗利用率为58.4%(95%可信区间:57.6 - 58.9),而实际利用率为28.5%(95%可信区间:28.0 - 31.5)。满足需求所需的放疗设备估计数量在1585至2545台之间。 结论:该研究凸显了所有癌症类型放疗利用方面的巨大缺口,并强调需要采取干预措施来填补公平癌症治疗所需设备的差距。该国减轻癌症负担的努力将通过早期诊断和治疗影响放疗需求。需要密切关注其他治疗方式的进展。
Health Technol Assess. 2006-9
Arch Ital Urol Androl. 2025-6-30
JBI Database System Rev Implement Rep. 2016-4
Cochrane Database Syst Rev. 2018-9-19
Health Technol Assess. 2024-10
Cochrane Database Syst Rev. 2021-4-19
JCO Glob Oncol. 2021-6
JCO Glob Oncol. 2020-7
Cancer J. 2020
Indian J Cancer. 2019